Antibiotic to prevent infections after acute kidney injury
Part of Kidney & urinary, Women’s health & pregnancy clinical trials.
This trial tests a preventive antibiotic (a combination of two drugs) to see if it can reduce the chance of infections after leaving the hospital in people who had acute kidney injury (sudden kidney failure) during their stay. It is intended for people who are recovering and about to go home or to a rehabilitation facility.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be at least 18 years old.
- Had acute kidney injury (sudden kidney failure) during the most recent hospital stay.
- Plan to go home or to a rehab facility and be able to attend follow-up visits.
- Not be allergic to sulfa drugs or the antibiotic Bactrim/Septra.
- Not be pregnant or breastfeeding.
- Have no severe liver disease, very low blood cell counts, or very high potassium levels that can't be corrected.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests if the drug AST-120 (Kremezin) can help protect your kidneys and slow down further kidney decline after a recent acute kidney injury. It is for people who had a moderate to severe kidney injury during a hospital stay and now have mild to moderate chronic kidney damage.
This study looks at whether continuing an antibiotic called TMP-SMX (Bactrim) for longer helps prevent urinary tract infections after a kidney transplant. If you've already taken it safely for 6 months, you may qualify to continue it for another 6 months or stop, to see which is better.
This trial compares two common antibiotic combinations to see which one is less likely to cause kidney injury in hospitalized patients. You may be eligible if you need treatment with vancomycin plus either piperacillin-tazobactam or cefepime.
This study looks at giving anti-infection medications (antibiotics) in a more personalized way soon after a kidney transplant. By carefully adjusting the dose, doctors hope to prevent infections while keeping the new kidney safe.
This study compares a lower dose versus the standard dose of the antibiotic TMP-SMX (Bactrim) to prevent a type of lung infection (Pneumocystis pneumonia) after a kidney transplant. If you are eligible, you will receive either a lower or standard dose to see which works just as well with fewer side effects.
This trial tests how long kidney transplant patients should take a common antibiotic (sulfamethoxazole) to prevent a lung infection called PJP. You may join if you are between 18 and 70 and have had a kidney transplant.
Hear when a new Acute Kidney Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.